U-NEURON’s Amniotic Fluid Stem Cell New Drug Secures Dual ExpeditedRegulatory Guidance for Regenerative Medicine

U-NEURON (6973-TW) announced today (22nd) that its proprietary new drug candidate UA002, designed for the treatment of erectile dysfunction, has been approved by Taiwan TFDA under the "Project-Based Advisory and Guidance Cases" scheme. Concurrently, UA002 secured the "Flagship Project" (Index Case) qualification from the Center for Drug Evaluation (CDE). Under this dedicated advisory framework, the company expects to accelerate development and regulatory review while mitigating R&D risks, marking dual expeditedregulatory support in the regenerative medicine arena.
Continue reading